Evaluation of an indirect NaV1.7 inhibitor as adjunctive analgesic in burn-related neuropathic pain in a cat
Veterinary Anaesthesia and Analgesia · 2025
DOI: 10.1016/j.vaa.2025.01.004 ↗Kurz gefasst
Fallbericht in der Zeitschrift Veterinary Anaesthesia and Analgesia, 2025. Verfasst von Ludovica Chiavaccini und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Comparative, Diagnostic and Population Medicine, University of Florida, College of Veterinary Medicine, Gainesville, FL, USA. Electroni…. Hauptthemen laut MEDLINE: Neuralgia, Analgesics, Cat Diseases, Burns. Die Arbeit nennt 13 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NINDS NIH HHS, National Center for Advancing Translational Sciences.
Abstract (Originalsprache)
Burn-related neuropathic pain (BRNP) can arise following burn-induced nerve damage, affects approximately 6% of burned human patients and can result in chronic pain. Although widely studied in humans, data on BRNP or its treatment in animals is lacking. A 4-year-old domestic shorthair cat was presented with an infected, non-healing wound suspected to be a caustic burn. Initial treatments included surgical debridement, antimicrobials, and corticosteroids, but the cat developed persistent pruritus leading to self-inflicted trauma. Despite various interventions, including prednisone, chloramphenicol and cyclosporine, clinical signs persisted, leading to a referral for suspected BRNP. Additional support for neuropathic pain was provided through thermal sensitivity testing and applying a modified Neuropathic Pain Symptoms Inventory. Treatment with gabapentin, amantadine, and acupuncture yielded little improvement, prompting an increasing escalation in gabapentin dosage. The cat was then treated with gabapentin compounded with compound 194, a small molecule that is a potent and selective inhibitor of voltage-gated sodium channel 1.7 (NaV1.7). The cat exhibited significant pain relief and improvements in overall condition. After gabapentin was tapered, compound 194 effectively maintained pain control. The cat's clinical condition stabilized with no adverse effects. Hematology and serum biochemistry results remained within reference intervals throughout the treatment period. This case highlights the potential of NaV1.7 inhibitors in multimodal management of neuropathic pain in animals.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Comparative, Diagnostic and Population Medicine, University of Florida, College of Veterinary Medicine, Gainesville, FL, USA. Electronic address: lchiavaccini@ufl.edu.
- Department of Small Animal Clinical Sciences, University of Florida, College of Veterinary Medicine, Gainesville, FL, USA.
- Department of Comparative, Diagnostic and Population Medicine, University of Florida, College of Veterinary Medicine, Gainesville, FL, USA.
- Department of Pharmacology and Therapeutics, University of Florida, College of Medicine, Gainesville, FL, USA.
Förderung
- NINDS NIH HHS
- National Center for Advancing Translational Sciences
Zitieren
APA
Chiavaccini, L., Santoro, D., Dwyer, C. E., Vettorato, E., Nelson, T. S., & Khanna, R. (2025). Evaluation of an indirect NaV1.7 inhibitor as adjunctive analgesic in burn-related neuropathic pain in a cat. Veterinary Anaesthesia and Analgesia. https://doi.org/10.1016/j.vaa.2025.01.004
Vancouver
Chiavaccini L, Santoro D, Dwyer CE, Vettorato E, Nelson TS, Khanna R. Evaluation of an indirect NaV1.7 inhibitor as adjunctive analgesic in burn-related neuropathic pain in a cat. Veterinary Anaesthesia and Analgesia. 2025. doi:10.1016/j.vaa.2025.01.004
BibTeX
@article{Chiavaccini2025,
author = {Chiavaccini, Ludovica and Santoro, Domenico and Dwyer, Colleen E and Vettorato, Enzo and Nelson, Tyler S and Khanna, Rajesh},
title = {Evaluation of an indirect NaV1.7 inhibitor as adjunctive analgesic in burn-related neuropathic pain in a cat},
journal = {Veterinary Anaesthesia and Analgesia},
year = {2025},
doi = {10.1016/j.vaa.2025.01.004}
}
EUVIMED